Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/Ib Open-Label Study of TAS4464 in Advanced Malignancies
jRCT2080223433Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS4464 in cancer, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of TAS4464, Pharmacokinetics of TAS4464 and 1 more. Started Jan 2017; status: completed.
02
Drugs
TAS4464
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2080223433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223433.